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The incidence of primary and metastatic brain tumors is 
increasing. As systemic cancer therapies continue to improve, 
the incidence of small intracranial lesions found on routine 
screening is expected to continue to increase. Though 
metastatic brain lesions occur more frequently than primary 
brain tumors, ten-percent of patients with a systemic cancer 
may present with a primary brain lesion. Treatments for 
metastatic and primary brain neoplasms differ, therefore it is 
often imperative to obtain a histopathologic diagnosis by direct 
tissue sampling. Stereotactic biopsy (STB) is the method of 
choice for sampling tissue from these lesions. However, this 
technique fails to obtain diagnostic tissue in 10-24% of cases. 
Failure to obtain diagnostic tissue delays initiation of 
personalized treatment plans and may result in further invasive 
procedures for patients. This project evaluates if coupling a 
novel in vivo optical imaging system with a STB system can 
verify acquisition of diagnostic tissue at the time of biopsy.
A fiberoptic imaging system was developed by coupling a 0.65mm diameter 
coherent fiberoptic bundle to an Olympus FLUOView 1000 microscope. 
Human U251 glioma cells expressing blue fluorescent protein (U251-BFP) 
were visualized with fluorescein contrast in in vitro and in vivo experiments. 
For animal experiments, a rodent was intracranial implanted with U251-BFP 
cells and administered fluorescein contrast 5 weeks post-implantation. A 
STB needle containing our 0.65mm imaging fiber was passed through a 
small cranial burr hole into the rodent’s brain. Fluorescence images from 
tumor and normal brain were obtained and quantitatively evaluated. 
Fluorescein demarcated the location of tumor cells in vitro. In vivo, fluorescein 
fluorescence intensity was 71.2% greater from tumor regions compared to 
contralateral normal brain regions (1532.0 ± 52.47 vs. 895 ± 9.349 RFU, 
p<0.001). 
Increasing the diagnostic yield of stereotactic biopsies may expedite and improve 
the overall care of neuro-oncology patients. We found that fluorescence imaging 
during STB can provide direct visualization of neoplastic tissue in an animal 
brain tumor model. This technique may complement clinical STB systems by 
providing a simple technique for verifying neoplastic tissue during biopsy. 
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Fluorescein differentiates tumor from 
normal brain in vivo. In vivo 
fluorescence endomicroscopy shows 
71.2% greater fluorescein fluorescence 
intensity from tumor regions compared 
to normal brain. Scale bar equals 20µm. 





Glioma- Blue Fluorescence Fluorescein Merge
In Vivo Fluorescence Endomicroscopy
Molecular imaging of fluorescent glioma cells and fluorescein contrast. Confocal microscopy confirms expression of blue 
fluorescent protein in modified human glioma cells. Fluorescein contrast delineates glioma cell bodies. Scale bar equals 20µm. 
Minimally invasive in vivo imaging. A) The imaging platform with a 0.65mm diameter fiber optic microendoscope. B) Our
microendoscope fits within the inner diameter of standard stereotactic biopsy needles. C) In vivo imaging and biopsies
performed through miniature craniotomies in animal models.
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